Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ANG Lifesciences IndiaBOM:540694 -3.35%63 PB Ratio is 0.76 as of Aug. 13, 2026, which is 22% below its 10-year median of 0.97. GuruFocus rates BOM:540694 with a GF Score™ of 63/100 and a GF Value™ of ₹30.13 (Fairly Valued). The stock has 3 warning signs investors should review. Among 920 Drug Manufacturers companies, ANG Lifesciences India ranks better than 84.46% on this metric.
The historical rank and industry rank for ANG Lifesciences India's PB Ratio or its related term are showing as below:
BOM:540694'
s PB Ratio Range Over the Past 10 Years
Min: 0.52 Med: 0.97 Max: 10.04
Current: 0.76
During the past 13 years, ANG Lifesciences India's highest PB Ratio was 10.04. The lowest was 0.52. And the median was 0.97.
BOM:540694's PB Ratio is ranked better than 84.46% of 920
companies
in the Drug Manufacturers industry
Industry Median: 1.99
vs BOM:540694: 0.76
During the past 12 months, ANG Lifesciences India's average Book Value Per Share Growth Rate was -17.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -15.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 0.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 28.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of ANG Lifesciences India was 95.20% per year. The lowest was -15.00% per year. And the median was 35.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, ANG Lifesciences India's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ANG Lifesciences India PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ANG Lifesciences India's PB Ratio distribution charts can be found below:
* The bar in red indicates where ANG Lifesciences India's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
ANG Lifesciences India (BOM:540694) has a PB Ratio of 0.76 as of Aug. 13, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ANG Lifesciences India and its competitors. This is 22% below median its historical median of 0.97. Over the past decade, ANG Lifesciences India's PB Ratio has ranged from 0.52 to 10.04. According to the industry distribution chart, ANG Lifesciences India ranks #143 out of 920 companies in the Drug Manufacturers industry, placing it in the top 15.5%.
Is ANG Lifesciences India's PB Ratio too high?
ANG Lifesciences India's current PB Ratio of 0.76 is 22% below median its 10-year median of 0.97. Over the past 10 years, this metric has ranged from a low of 0.52 to a high of 10.04. The Drug Manufacturers industry median PB Ratio is 1.99. ANG Lifesciences India's value of 0.76 is 61.8% below this industry median. Based on the distribution chart, ANG Lifesciences India ranks #143 out of 920 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, ANG Lifesciences India has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ANG Lifesciences India's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, ANG Lifesciences India ranks #143 out of 920 companies for PB Ratio. This places ANG Lifesciences India in the top 16% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.99. ANG Lifesciences India's value of 0.76 is 61.8% below this benchmark. Historically, ANG Lifesciences India's own PB Ratio has ranged from 0.52 to 10.04 over the past decade. While the company's 10-year median is 0.97 vs. the industry median of 1.99, ANG Lifesciences India has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.99, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ANG Lifesciences India's current PB Ratio of 0.76 is 61.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ANG Lifesciences India and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ANG Lifesciences India's current PB Ratio is 0.76, which is 22% below median its own 10-year median of 0.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ANG Lifesciences India stock overvalued right now?
Based on GuruFocus' analysis, ANG Lifesciences India (BOM:540694) is currently considered Fairly Valued. The stock's GF Value™ is ₹30.13, compared to a current price of ₹30.60 — trading 1.6% above its estimated fair value. The current PB Ratio is 0.76, which is 22% below median its 10-year median of 0.97 and 61.8% below the Drug Manufacturers industry median of 1.99. ANG Lifesciences India's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For ANG Lifesciences India (BOM:540694), the current PB Ratio is 0.76 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ANG Lifesciences India (BOM:540694) Overvalued in 2026?
Based on GuruFocus' analysis, ANG Lifesciences India stock appears to be overvalued.
The current stock price of ₹30.60 is trading 1.6% above its estimated GF Value™ of ₹30.13.
GuruFocus considers ANG Lifesciences India to be Fairly Valued.
Key valuation signals for BOM:540694:
PB Ratio: 0.76 (22% below median its 10-year median of 0.97)
GF Value™: ₹30.13 vs. price of ₹30.60 (1.6% above fair value)
Industry Position: 61.8% below the Drug Manufacturers median (#143 of 920)
No single metric tells the full story. See the BOM:540694 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ANG Lifesciences India Ltd is engaged in the business of manufacturing and sales of finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials, liquid injection vials, ampoules, PFS, hard gelatin capsules, soft gelatin capsules, dry syrups, liquid syrups and suspension, lotions, etc. Its product portfolio comprises various therapeutic categories such as antibiotics, antivirals, antimalarial, antiulcer, carbapenem, corticosteroid, penicillin, beta-lactamase inhibitor, etc. Through its subsidiary, it is also involved in the business of printing and packing solutions. The group's reportable segments are Pharmaceuticals, which derive maximum revenue, and Packaging and printing. Geographically, it derives maximum revenue from India.
63GF Score
Get the complete analysis for BOM:540694
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540694 has been successfully added to your 
